logo

Ultragenyx Pharmaceutical Inc (RARE)



Trade RARE now with
  Date
  Headline
10/14/2019 8:45:11 AM Ultragenyx Says FDA Accepted For Review NDA For UX007
9/3/2019 8:35:03 AM GeneTx And Ultragenyx: FDA Grant Orphan Drug Designation And Rare Pediatric Disease Designation To GTX-102
8/1/2019 8:37:40 AM Ultragenyx Submits NDA For UX007 For Long-Chain Fatty Acid Oxidation Disorders
5/7/2019 9:21:54 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) FY19 Rev. Estimate To 95.1 M From 116.8 M
5/7/2019 9:21:42 AM Wedbush Is Lowering Ultragenyx Pharmaceutical Inc (RARE) Q4 19 Rev. Estimate To 30.4 M From 37.3 M
5/7/2019 9:21:31 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) Q3 19 Rev. Estimate To 25.3 M From 31.2 M
5/7/2019 8:53:51 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) Q2 19 Rev. Estimate To 21.3 M From 26.3 M
5/7/2019 8:53:03 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) FY19 Estimate To -7.07 From -6.37
5/7/2019 8:52:43 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) Q4 19 Estimate To -1.73 From -1.41
5/7/2019 8:52:17 AM Wedbush Is Lowering Ultragenyx Pharmaceutical Inc (RARE) Q3 19 Estimate To -1.75 From -1.61
5/7/2019 8:50:52 AM Wedbush Is Lowering Ultragenyx Pharmaceutical Inc (RARE) Q2 19 Estimate To -1.76 From -1.65
5/6/2019 5:07:40 PM Ultragenyx Pharma Q1 Loss Per Share Of $1.82 Vs. $0.62 Last Year
3/26/2019 8:35:24 AM Ultragenyx Announces Approval Of Crysvita In Brazil For X-linked Hypophosphatemia In Adults And Children
2/19/2019 5:20:47 PM Ultragenyx Pharma Q4 Loss/share $1.73 Vs. Loss $1.89 Year Ago
2/4/2019 8:34:32 AM Ultragenyx Appoints Shehnaaz Suliman To Board
1/7/2019 7:35:27 AM Wedbush Reiterates Ultragenyx Pharmaceutical Inc (RARE) At Outperform With $88 Price Target
1/4/2019 8:34:43 AM Ultragenyx Reports Results From First Cohort Of Phase1/2 Study Of DTX401 GeneTherapy In Glycogen Storage Disease Type Ia
12/6/2018 8:39:50 AM Ultragenyx And Kyowa Kirin Announce Health Canada Approval Of Crysvita
  
 
>